• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aptar Pharma’s nasal spray compliance device wins EMA nod

May 15, 2017 By Sarah Faulkner

Aptar Pharma's lockout deviceAptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company.

The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals International (TYO:4502). Aptar agreed to supply its e-Lockout device for use with Takeda’s multi-dose nasal spray version of a fast-acting opioid, Instanyl.

Takeda plans to launch a uni-dose and multi-dose version of its nasal spray with Aptar’s electronic lockout system in Europe.

The device is intended to limit the number of doses available during a 24-hour period, in the hopes of boosting patient compliance.

Instanyl is indicated as a pain-reliever for breakthrough pain in adult cancer patients who are already taking opioids for their usual pain. Breakthrough pain refers to additional sudden pain that happens even though patients take their usual painkillers

Aptar’s e-Lockout device uses an electronic mechanism to prevent the device from being used for a period of time after a pre-defined number of doses. The display shows the number of doses left in the device and whether the spray is locked or available for use. The device also has a child-resistant cap.

“This approval and subsequent product launch underscores Aptar Pharma’s ability to partner with the pharma industry to bring innovative, compliant and safer devices through the regulatory authorization process,” Aptar Pharma’s president, Salim Haffar, said in prepared remarks. “This is yet another example of Aptar Pharma’s expertise and technology at the heart of a new market launch. This is a significant step in strengthening Aptar Pharma’s credentials in the electronics and connected health markets. We are pleased to be building on our trusted, long-term partnership with Takeda.”

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: aptarpharma, Takeda Pharmaceutical Co

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS